blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3786287

EP3786287 - CD3-NEGATIVE CELL POPULATION EXPRESSING CHEMOKINE RECEPTOR AND CELL ADHESION MOLECULE, USE THEREOF, AND METHOD FOR PRODUCING SAME [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  29.01.2021
Database last updated on 29.06.2024
FormerThe international publication has been made
Status updated on  05.10.2019
Most recent event   Tooltip16.02.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
GAIA BioMedicine Inc.
1-10-9-903 Kego
Chuo-ku
Fukuoka-shi
Fukuoka 810-0023 / JP
For all designated states
Yonemitsu, Yoshikazu
1-10-9-903, Kego
Chuo-ku
Fukuoka-shi, Fukuoka 810-0023 / JP
[2021/09]
Inventor(s)01 / HARADA, Yui
c/o KYUSHU UNIVERSITY, NATIONAL UNIVERSITY
CORPORATION, 744, Motooka, Nishi-ku
Fukuoka-shi, Fukuoka 819-0395 / JP
02 / YONEMITSU, Yoshikazu
1-10-9-903, Kego, Chuo-ku
Fukuoka-shi, Fukuoka 810-0023 / JP
 [2021/09]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2021/09]
Application number, filing date19775565.526.03.2019
[2021/09]
WO2019JP12744
Priority number, dateJP2018005962427.03.2018         Original published format: JP 2018059624
[2021/09]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019189115
Date:03.10.2019
Language:JA
[2019/40]
Type: A1 Application with search report 
No.:EP3786287
Date:03.03.2021
Language:EN
[2021/09]
Search report(s)International search report - published on:JP03.10.2019
(Supplementary) European search report - dispatched on:EP14.12.2021
ClassificationIPC:C12N5/0783, A61K35/17, A61P35/00
[2021/09]
CPC:
C07K14/705 (EP,KR); C12N5/0646 (EP,KR,US); A61K35/17 (US);
A61K39/4613 (EP,KR); A61K39/4644 (EP,KR); A61P35/00 (EP,KR,US);
C07K14/70503 (EP); C07K14/7051 (EP,KR); C07K14/7158 (EP,KR);
C12N5/0081 (EP,US); A61K2239/31 (EP,KR); A61K2239/38 (EP,KR);
A61K2239/59 (EP,KR); C12N2501/21 (EP); C12N2501/2302 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/09]
TitleGerman:CHEMOKIN-REZEPTOR EXPRIMIERENDE CD3-NEGATIVE ZELLPOPULATION UND ZELLADHÄSIONSMOLEKÜL, VERWENDUNG DAVON UND HERSTELLUNGSVERFAHREN DAFÜR[2021/09]
English:CD3-NEGATIVE CELL POPULATION EXPRESSING CHEMOKINE RECEPTOR AND CELL ADHESION MOLECULE, USE THEREOF, AND METHOD FOR PRODUCING SAME[2021/09]
French:POPULATION DE CELLULES CD3 NÉGATIVES EXPRIMANT UN RÉCEPTEUR DE CHIMIOKINE ET UNE MOLÉCULE D'ADHÉRENCE CELLULAIRE, ET APPLICATION AINSI QUE PROCÉDÉ DE FABRICATION ASSOCIÉS[2021/09]
Entry into regional phase26.10.2020Translation filed 
26.10.2020National basic fee paid 
26.10.2020Search fee paid 
26.10.2020Designation fee(s) paid 
26.10.2020Examination fee paid 
Examination procedure26.10.2020Examination requested  [2021/09]
22.07.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
12.03.2021Renewal fee patent year 03
15.02.2022Renewal fee patent year 04
15.02.2023Renewal fee patent year 05
15.02.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2003068306  (DILBER MEHMET SIRAC [SE]) [Y] 1-10* claims 1-17 *;
 [Y]EP2725100  (UNIV KYUSHU NAT UNIV CORP [JP], et al) [Y] 1-10 * examples 1,2; claims 1-11 *;
 [X]  - SATORU SAITO ET AL, "Ex Vivo Generation of Highly Purified and Activated Natural Killer Cells from Human Peripheral Blood", HUMAN GENE THERAPY METHODS, (20130801), vol. 24, no. 4, doi:10.1089/hgtb.2012.183, ISSN 1946-6536, pages 241 - 252, XP055154762 [X] 1-10 * page 242, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1089/hgtb.2012.183
 [Y]  - TAKAHASHI E ET AL, "Induction of CD16(+) CD56(bright) NK cells with antitumour cytotoxicity not only from CD16(-) CD56(bright) NK cells but also from CD16(-) CD56(dim) NK cells", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, (20070201), vol. 65, no. 2, doi:10.1111/J.1365-3083.2006.01883.X, ISSN 0300-9475, pages 126 - 138, XP002528954 [Y] 1-10 * page 127, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1111/j.1365-3083.2006.01883.x
International search[A]JP2013027385  (UNIV KYUSHU, et al) [A] 1-10* ( *;
 [XA]  - TAKAHASHI E. et al., "Induction of CD 16+ CD 56bright NK cells with antitumour cytotoxicity not only from CD 16- CD 56bright NK cells but also from CD 16- CD 56dim NK cells", Scand. J. Immunol., (20070000), vol. 65, no. 2, doi:doi:10.1111/j.1365-3083.2006.01883.x, pages 126 - 138, XP002528954 [X] 1, 4-7, 9-10 * (Abstract, Figure 2, 7) * [A] 2-3, 8

DOI:   http://dx.doi.org/10.1111/j.1365-3083.2006.01883.x
 [A]  - BERAHOVICH R.D. et al., "Evidence for NK cell subsets based on chemokine receptor expression", J. Immunol., (20061201), vol. 177, no. 11, pages 7833 - 7840, XP055638851 [A] 1-10 * (FIGURE 6, Table III) *

DOI:   http://dx.doi.org/10.4049/jimmunol.177.11.7833
 [A]  - POLI A. et al., "CD 56bright natural killer (NK) cells: an important NK cell subset", Immunology, (20090000), vol. 126, no. 4, pages 458 - 465, XP002536329 [A] 1-10 * (Table 1) *
 [A]  - LEVI I. et al., "Characterization of tumor infiltrating natural killer cell subset", Oncotarget, (20150323), vol. 6, no. 15, pages 13835 - 13843, XP055638853 [A] 1-10 * (ABSTRACT, Figures) *

DOI:   http://dx.doi.org/10.18632/oncotarget.3453
 [A]  - SAITO S. et al., "Ex Vivo generation of highly purified and activated natural killer cells from human peripheral blood. Hum", Gene Ther. Methods, (20130000), vol. 24, no. 2, doi:doi:10.1089/hgtb.2012.183, pages 241 - 252, XP055154762 [A] 1-10 * (Abstract, FIGS.) *

DOI:   http://dx.doi.org/10.1089/hgtb.2012.183
by applicantJP2013027385
 JP2013515497
 JP5572863B
 JP2018059624
    - MELERO I. et al., Cancer Discovery, (20140000), vol. 4, pages 522 - 526
    - JENA B et al., Blood, (20180000), vol. 116, pages 1035 - 1044
    - MOON E et al., Clin. Cancer Res., (20110000), vol. 17, no. 14, pages 4719 - 4730
    - LIMA M et al., Journal of Immunology Research, vol. 2015, page 18
    - MAENPAA et al., Int. J. Cancer, (19930000), vol. 53, pages 850 - 855
    - HIRSCHHAEUSER F et al., J. Biotechnol., (20100701), vol. 148, no. 1, pages 3 - 15
    - XIANG X et al., PLoS ONE, (20110000), vol. 6, no. 1, page e14640
    - MILOTTI E.CHIGNOLA R., PLoS ONE, (20100000), vol. 5, no. 11, page e13942
    - DORONIN et al., BMC Cancer, (20140000), vol. 14, page 295
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.